What Matters Most? An Exploration of Decision Criteria Considered by Patients with GEP-NET and Physicians Using Holistic Multi-Criteria Decision Analysis Abstract #1628

Introduction: Patient-centered care means identifying what matters most through shared decision making. EVIDEM provides an MCDA platform to explore decision criteria and tradeoffs.
Aim(s): We developed a holistic decision support framework to identify preferences of patients and physicians in the management of unresectable, well- or moderately differentiated non-functioning GEP-NET.
Materials and methods: Design of the framework was led by EVIDEM structure, literature review and insights from a Chatham-house panel of physicians and patients. During a second panel, 5 patients and 6 physicians weighed criteria using Hierarchical Point Allocation and Direct Rating Scale (DRS, sensitivity analysis). Insights were collected in discussions and individually.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: ...none of the above
Presenting Author: Dima Samaha

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1629 To Treat or Watch? Identifying Drivers of Decisions for Patients with GEP-NET Using Reflective Multi-Criteria Decision Analysis
Introduction: Somatostatin analogs (SSAs) or watchful-waiting are recommended for unresectable, well- or moderately-differentiated non-functioning GEP-NET.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Others
Presenting Author: Dima Samaha
#641 Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) Management in a Spanish University Hospital
Introduction: GEP-NETs are malignant entities poorly understood still, deserving important attention for a better management of the disease.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Msc MD María Del Pilar Solis-Hernandez
#1563 Impact of Early Surgery on Prognosis in Advanced Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET)
Introduction: In gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) the role of surgery remains to be determined.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Surgical treatment
Presenting Author: MD Patrizia Kump
#2956 Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis
Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Marion Feuilly
#2137 Evaluation of Multidisciplinary Tumor Board Decisions in the Management of Neuroendocrine Tumors: Impact of Expert Centers
Introduction: ENETS requires Centers of Excellence to discuss all new gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients in a multidisciplinary tumor board (MDT) but the true value of the MDT has never been assessed
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Wouter Zandee